Aura Biosciences Completes Enrollment in Pivotal Phase 3 CoMpass Trial for Bel-sar; Topline Data Expected H2 2027
AURA sits 58% above its 52-week low of $4.73.
Summary
Aura Biosciences has completed enrollment of 108 patients in its pivotal Phase 3 CoMpass trial for bel-sar, targeting early choroidal melanoma. This significant operational milestone follows the company's recent successful capital raise in May, which secured its financial position and extended its cash runway. The trial, which has a Special Protocol Assessment (SPA) agreement with the FDA, moves the lead candidate closer to potential regulatory approval. Topline data from the 15-month primary endpoint are expected in the second half of 2027.
At the time of this announcement, AURA was trading at $7.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $772.3M. The 52-week trading range was $4.73 to $9.54. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.